SavedAdd your journal

Journals / BEYOGLU EYE JOURNAL / 2021 / Cilt: 6 - Sayı: 3

Evaluation of Serum Concentration of the Myokine Irisin (FNDC5) in Patients with Age-Related Macular Degeneration

Burak TURGUT
Kadir MERCAN
NEVİN İLHAN
Selahattin Semih AYDOĞAN
Pages
180–184
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The results suggest that the serum irisin level in ARMD patients is not different from that of healthy individuals.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study evaluated the serum irisin level of patients with age-related macular degeneration (ARMD) and compared it with that of healthy individuals.
📊
Key Findings & Data:Methods: The serum irisin level of 15 healthy controls (Group 1) and 15 dry ARMD patients (Group 2) and 15 wet ARMD patients (Group 3) were measured using the enzyme-linked immunosorbent assay (ELISA) method and compared.
💡
Conclusion & Impact:Conclusion: The results suggest that the serum irisin level in ARMD patients is not different from that of healthy individuals.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: This study evaluated the serum irisin level of patients with age-related macular degeneration (ARMD) and compared it with that of healthy individuals. Methods: The serum irisin level of 15 healthy controls (Group 1) and 15 dry ARMD patients (Group 2) and 15 wet ARMD patients (Group 3) were measured using the enzyme-linked immunosorbent assay (ELISA) method and compared. Results: There was no statistically significant difference between the groups in terms of age or gender (p>0.05). The mean serum irisin levels of Group 1, Group 2, and Group 3 were 25.81±24.04 ng/mL, 22.93±19.05 ng/mL, and 12.38±8.16 ng/mL, respectively. Although the mean irisin level in the wet ARMD patients was lower than that of the control and dry ARMD groups, there was no statistically significant difference between the groups (p>0.05). Conclusion: The results suggest that the serum irisin level in ARMD patients is not different from that of healthy individuals. Studies of larger groups that examine the irisin level in the vitreous and neovascular membranes will further elucidate any role in the pathogenesis of ARMD.

🔖

Cite This Article

TURGUT, B., MERCAN, K., İLHAN, N., AYDOĞAN, S. S. (2021). Evaluation of Serum Concentration of the Myokine Irisin (FNDC5) in Patients with Age-Related Macular Degeneration. BEYOGLU EYE JOURNAL, Cilt: 6 - Sayı: 3, 180–184. https://ajindex.com/articles/396504

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Kniggendorf V, Dreyfuss JL, Regatieri CV. Age-related macular degeneration: a review of current therapies and new treatments. Arq Bras Oftalmol 2020;83:552–61
  2. Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron 2012;75:26–39
  3. Wu J, Sun X. Complement system and age-related macular degeneration: drugs and challenges. Drug Des Devel Ther 2019;13:2413–25
  4. Tsai DC, Charng MJ, Lee FL, Hsu WM, Chen SJ. Different plasma levels of vascular endothelial growth factor and nitric oxide between patients with choroidal and retinal neovascularization. Ophthalmologica 2006;220:246–51
  5. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008;27:331–71
  6. Wallace GR, John Curnow S, Wloka K, Salmon M, Murray PI. The role of chemokines and their receptors in ocular disease. Prog Retin Eye Res 2004;23:435–48
  7. Kniggendorf V, Dreyfuss JL, Regatieri CV. Age–related macular degeneration: a review of current therapies and new treatments. Arq Bras Oftalmol 2020;83:552–61
  8. Teufel A, Malik N, Mukhopadhyay M, Westphal H. Frcp1 and Frcp2, two novel fibronectin type III repeat containing genes. Gene 2002;297:79–83
  9. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012;481:463– 8
  10. Schumacher MA, Chinnam N, Ohashi T, Shah RS, Erickson HP. The structure of irisin reveals a novel intersubunit β-sheet fibronectin type III (FNIII) dimer: implications for receptor activation. J Biol Chem 2013;288:33738–44
  11. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012;61:1725–38
  12. Gençer Tarakçı B, Girgin A, Timurkaan S, Yalçın MH, Gür FM, Karan M. Immunohistochemical localization of irisin in skin, eye, and thyroid and pineal glands of the crested porcupine (Hystrix cristata). Biotech Histochem 2016;91:423–7
  13. Gür FM, Timurkaan S, Gençer Tarakçi B, Yalçin MH, Özkan ZE, Baygeldi SB, et al. Identification of immunohistochemical localization of irisin in the dwarf hamster (Phodopus roborovskii) tissues. Anat Histol Embryol 2018;47:174–9
  14. Gouveia MC, Vella JP, Cafeo FR, Affonso Fonseca FL, Bacci MR. Association be